Tacket C O, Hone D M, Curtiss R, Kelly S M, Losonsky G, Guers L, Harris A M, Edelman R, Levine M M
Department of Medicine, University of Maryland School of Medicine, Baltimore 21201.
Infect Immun. 1992 Feb;60(2):536-41. doi: 10.1128/iai.60.2.536-541.1992.
Three attenuated Salmonella typhi strains have been constructed by introducing deletions in aroC and aroD or deletions in cya and crp into one of two wild-type parent strains, Ty2 or ISP1820. These mutant strains were designated CVD 906 (ISP1820 delta aroC delta aroD), CVD 908 (Ty2 delta aroC delta aroD), and chi 3927 (Ty2 delta cya delta crp). Two studies were conducted with 36 healthy adult inpatient volunteers to determine in a double-blind fashion the safety and immunogenicity of approximately 5 x 10(4) and 5 x 10(5) CFU of each of these three vaccine candidates given as a single dose. No statistically significant difference in the incidence of reactions among vaccinees was observed. Fever (oral temperature greater than or equal to 38.2 degrees C) occurred in 2 of 12 volunteers who received CVD 906, in 0 of 12 who received CVD 908, and in 1 of 12 who received chi 3927. Vaccine bacteremia without symptoms occurred in 1 of 12 vaccinees who received CVD 906, in 0 of 12 who received CVD 908, and in 2 of 12 who received chi 3927. Overall, 19 (53%) of 36 vaccinees developed immunoglobulin G antibody to S. typhi lipopolysaccharide after vaccination, with no statistically significant differences in the rate of seroconversion among volunteers in the three groups. We conclude that defined mutations in the aromatic biosynthetic pathway and in the cyclic AMP global regulatory system attenuate S. typhi. Mutant strains CVD 906, CVD 908, and chi 3927 are highly (and approximately equally) immunogenic but possibly differ in their propensity to induce fever. Further studies are needed to document the apparent relative safety of CVD 908 as a typhoid vaccine and as a vaccine carrier of foreign antigens.
通过在aroC和aroD基因中引入缺失或在cya和crp基因中引入缺失,已构建出三种减毒伤寒沙门氏菌菌株,分别导入两种野生型亲本菌株(Ty2或ISP1820)之一中。这些突变菌株分别命名为CVD 906(ISP1820 ΔaroC ΔaroD)、CVD 908(Ty2 ΔaroC ΔaroD)和chi 3927(Ty2 Δcya Δcrp)。对36名健康成年住院志愿者进行了两项研究,以双盲方式确定这三种候选疫苗各以约5×10⁴和5×10⁵CFU单剂量给药后的安全性和免疫原性。在疫苗接种者中未观察到反应发生率有统计学显著差异。接受CVD 906的12名志愿者中有2人出现发热(口腔温度大于或等于38.2℃),接受CVD 908的12名志愿者中无人发热,接受chi 3927的12名志愿者中有1人发热。接受CVD 906的12名疫苗接种者中有1人出现无症状的疫苗菌血症,接受CVD 908的12名志愿者中无人出现,接受chi 3927的12名志愿者中有2人出现。总体而言,36名疫苗接种者中有19人(53%)在接种疫苗后产生了针对伤寒沙门氏菌脂多糖的免疫球蛋白G抗体,三组志愿者的血清转化率无统计学显著差异。我们得出结论,芳香族生物合成途径和环磷酸腺苷全局调节系统中的特定突变可使伤寒沙门氏菌减毒。突变菌株CVD 906、CVD 908和chi 3927具有高度(且大致相同)的免疫原性,但在诱导发热的倾向方面可能有所不同。需要进一步研究来证明CVD 908作为伤寒疫苗和外来抗原疫苗载体的明显相对安全性。